Phio Pharmaceuticals Corp (PHIO)

[wildbullus]

RXi Could Sign the Next Deal

http://biotechstocktrader.com/rxi-pharmaceuticals-benefit-biotech-industry-dynamics/

RXi Pharmaceuticals recently reported positive results for its first and second Phase I multi-dose study of RXI-109 for the treatment of dermal scarring in patients with hypertrophic scars and keloids. The studies showed a reduction in CTGF mRNA in line with its mechanism of action and in a dose-dependent manner and was well tolerated at all doses. With the favorable results in hand, management is gearing up to begin a Phase II study.

While RXI-109’s results have been positive, the company’s real potential lies in licensing its sd-rxRNA platform to larger pharmaceutical companies through collaborations similar to Alnylam’s alliance with Sanofi or Isis’ deal with Biogen. The self-delivering RNAi platform has demonstrated spontaneous cellular uptake and a significant, sustained and reproducible silencing of the targeted mRNA in a market where delivery is exceedingly important.